Merck may be at the forefront of cancer care innovation, but an EU regulatory agency decided not to play “NICE” when it came to drug pricing.
Merck may be at the forefront of cancer care innovation, but an EU regulatory agency decided not to play “NICE” when it came to drug pricing.